BioSpace News Archive

Business

Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST

Processa Pharmaceuticals, Inc. announces today it will host a conference call and live webcast on May 12, 2022 at 4:30 p.m. EST to discuss its results for the first quarter and provide an update on its clinical pipeline.

May 5, 2022
·
2 min read
Genetown

Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

Biofrontera Inc. announced its sponsorship of the 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, being held May 11-15, 2022 in Nashville, Tenn.

May 5, 2022
·
5 min read
Biotech Beach

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), presented data from its Atlas Continuation study on the negative impact Demodex blepharitis has on daily life and visual function among certain patient groups, as well as preliminary findings from the Pandora study on coexisting bacterial burden for patients with Demodex blepharitis.

May 5, 2022
·
5 min read
Biotech Bay

BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations

BioMarin Pharmaceutical Inc. today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.

May 5, 2022
·
7 min read
Lone Star Bio

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

Genprex, Inc. announced that it has issued a shareholder letter and corporate update outlining the Company’s recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond.

May 5, 2022
·
5 min read
Researchers at the Gwangju Institute of Science and Technology Develop Deep Learning Model to Predict Adverse Drug-Drug Interactions

The intake of multiple drugs can result in adverse health effects due to unexpected drug-drug interactions.

May 5, 2022
·
3 min read
Business

Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference

Anixa Biosciences, Inc. today announced that it will present a company update at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 (Hybrid Conference).

May 5, 2022
·
3 min read
Drug Development

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Phase 3 SPOTLIGHT Study of Targeted PET Imaging Agent 18 F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer.

May 5, 2022
·
4 min read
Biotech Bay

InterVenn Biosciences to Present at the Bank of America 2022 Healthcare Conference

InterVenn Biosciences, the leader in glycoproteomics, today announced Aldo Carrascoso, Co-Founder and CEO, will present at the Bank of America 2022 Healthcare Conference on Tuesday, May 10, 2022 in Las Vegas, NV.

May 5, 2022
·
1 min read
Biotech Beach

U.S. FDA Renews Annual DILIsym Software Licenses for 2022

Simulations Plus, Inc. (Nasdaq: SLP), today announced that the U.S. Food and Drug Administration (FDA) has renewed its licenses to the DILIsym® software platform, the DILIsym Services division’s flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

May 5, 2022
·
4 min read